Regeneron Pharmaceuticals Executive Vice President and General Manager, Industrial Operations and Product Supply Daniel Van Plew's 2021 pay rises 1% to $8.8M
Regeneron Pharmaceuticals reports 2021 executive compensation
By ExecPay News
Published: April 21, 2022
Regeneron Pharmaceuticals reported fiscal year 2021 executive compensation information on April 21, 2022.
In 2021, six executives at Regeneron Pharmaceuticals received on average a compensation package of $7.4M, a 88% decrease compared to previous year.
Average pay of disclosed executives at Regeneron Pharmaceuticals
Daniel Van Plew, Executive Vice President and General Manager, Industrial Operations and Product Supply, received $8.8M in total, which increased by 1% compared to 2020. 48% of Van Plew's compensation, or $4.2M, was in option awards. Van Plew also received $931K in non-equity incentive plan, $823K in salary, $2.8M in stock awards, as well as $21K in other compensation.
Robert E. Landry, Chief Financial Officer, received a compensation package of $8.3M, which increased by 34% compared to previous year. 46% of the compensation package, or $3.8M, was in option awards.
Andrew J. Murphy, Executive Vice President, Research, earned $7.1M in 2021, a 35% decrease compared to previous year.
Joseph J. LaRosa, General Counsel, received $7.1M in 2021.
Leonard S. Schleifer, Chief Executive Officer, earned $6.5M in 2021, a 95% decrease compared to previous year.
George D. Yancopoulos, Chief Scientific Officer, received $6.4M in 2021, which decreases by 95% compared to 2020.
Related executives
Leonard Schleifer
Regeneron Pharmaceuticals
Chief Executive Officer
George Yancopoulos
Regeneron Pharmaceuticals
Chief Scientific Officer
Robert Landry
Regeneron Pharmaceuticals
Chief Financial Officer
Daniel Van Plew
Regeneron Pharmaceuticals
Executive Vice President and General Manager, Industrial Operations and Product Supply
Andrew Murphy
Regeneron Pharmaceuticals
Executive Vice President, Research
Joseph LaRosa
Regeneron Pharmaceuticals
General Counsel
You may also like
Source: SEC filing on April 21, 2022.